Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Pharmacology

Background:

• Development of selective enzyme inhibitors is crucial for therapeutic applications.
• Thrombin and trypsin are serine proteases with distinct physiological roles.
• Existing inhibitors may face challenges in selectivity or pharmacokinetic properties.

Purpose of the Study:

• To design and synthesize novel azaindole derivatives as potent enzyme inhibitors.
• To enhance selectivity for thrombin compared to trypsin.
• To evaluate the pharmacokinetic and in vitro efficacy of lead compounds.

Main Methods:

• Structure-based drug design starting from a 2-amino-6-methylpyridine scaffold.
• Chemical synthesis and structural modification to reduce polarity and enlarge the P1 group.
• In vitro enzymatic assays to determine selectivity (thrombin vs. trypsin).
• Pharmacokinetic studies in dogs following oral administration.
• In vitro efficacy assessments.

Main Results:

• A series of moderately basic azaindoles were successfully synthesized.
• These azaindoles demonstrated significantly improved selectivity for thrombin over trypsin.
• Specific pyrazinone acetamide azaindole derivatives exhibited comparable oral pharmacokinetics and in vitro efficacy to an optimized 2-amino-6-methylpyridine derivative.

Conclusions:

• The developed azaindole series represents a promising class of selective thrombin inhibitors.
• Structural modifications effectively improved enzyme selectivity and pharmacokinetic properties.
• These findings support the potential of azaindoles as therapeutic agents targeting thrombin.